Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 3150.

https://doi.org/10.1182/blood.V128.22.3150.3150

Published: 2016

Journal Articles

Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MDPhD, Yuko Tanaka, MDPhD, Juri Sakuta, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 3693.

https://doi.org/10.1182/blood.V126.23.3693.3693

Published: 2015

Journal Articles

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kaoru Tohyama, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 791.

https://doi.org/10.1182/blood.V126.23.791.791

Published: 2015

Journal Articles

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL Point Mutation

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MDPhD, Yuko Tanaka, MDPhD, Juri Sakuta, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 2769.

https://doi.org/10.1182/blood.V126.23.2769.2769

Published: 2015

Journal Articles

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MDPhD, Seiichiro Katagiri, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 3127.

https://doi.org/10.1182/blood.V124.21.3127.3127

Published: 2014

Journal Articles

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

Yuko Tanaka, MDPhD, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 5755.

https://doi.org/10.1182/blood.V124.21.5755.5755

Published: 2014

Journal Articles

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD PhD, Seiichiro Katagiri, MD, Seiichi Okabe, MD PhD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD, PhD

Blood (2014) 124 (21): 905.

https://doi.org/10.1182/blood.V124.21.905.905

Published: 2014

NARROW

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL Point Mutation

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Email alerts

ASH Publications

American Society of Hematology

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL Point Mutation

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only